Literature DB >> 21255496

Neurally adjusted ventilatory assist: a ventilation tool or a ventilation toy?

Walter Verbrugghe1, Philippe G Jorens.   

Abstract

Mechanical ventilation has, since its introduction into clinical practice, undergone a major evolution from controlled ventilation to various modes of assisted ventilation. Neurally adjusted ventilatory assist (NAVA) is the newest development. The implementation of NAVA requires the introduction of a catheter to measure the electrical activity of the diaphragm (EA(di)). NAVA relies, opposite to conventional assisted ventilation modes, on the EA(di) to trigger the ventilator breath and to adjust the ventilatory assist to the neural drive. The amplitude of the ventilator assist is determined by the instantaneous EA(di) and the NAVA level set by the clinician. The NAVA level amplifies the EA(di) signal and determines instantaneous ventilator assist on a breath-to-breath basis. Experimental and clinical data suggest superior patient-ventilator synchrony with NAVA. Patient-ventilator asynchrony is present in 25% of mechanically ventilated patients in the intensive care unit and may contribute to patient discomfort, sleep fragmentation, higher use of sedation, development of delirium, ventilator-induced lung injury, prolonged mechanical ventilation, and ultimately mortality. With NAVA, the reliance on the EA(di) signal, together with an intact ventilatory drive and intact breathing reflexes, allows integration of the ventilator in the neuro-ventilatory coupling on a higher level than conventional ventilation modes. The simple monitoring of the EA(di) signal alone may provide the clinician with important information to guide ventilator management, especially during the weaning process. Although, until now, little evidence proves the superiority of NAVA on clinically relevant end points, it seems evident that patient populations (eg, COPD and small children) with major patient-ventilator asynchrony may benefit from this new ventilatory tool.

Entities:  

Mesh:

Year:  2011        PMID: 21255496     DOI: 10.4187/respcare.00775

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  9 in total

1.  Inappropriate use of neurally adjusted ventilator assist.

Authors:  Francesca Iodice; Giuseppina Testa; Antonio Amodeo; Paola Cogo
Journal:  BMJ Case Rep       Date:  2012-09-03

2.  The pharmacology of acute lung injury in sepsis.

Authors:  Brian Michael Varisco
Journal:  Adv Pharmacol Sci       Date:  2011-06-28

Review 3.  Newer nonconventional modes of mechanical ventilation.

Authors:  Preet Mohinder Singh; Anuradha Borle; Anjan Trikha
Journal:  J Emerg Trauma Shock       Date:  2014-07

4.  A Comparative Data-Based Modeling Study on Respiratory CO2 Gas Exchange during Mechanical Ventilation.

Authors:  Chang-Sei Kim; J Mark Ansermino; Jin-Oh Hahn
Journal:  Front Bioeng Biotechnol       Date:  2016-02-03

5.  Combined use of Neurally Adjusted Ventilatory Assist (NAVA) and Vertical Expandable Prostethic Titanium Rib (VEPTR) in a patient with Spondylocostal dysostosis and associated bronchomalacia.

Authors:  Martí Pons-Odena; Alba Verges; Natalia Arza; Francisco José Cambra
Journal:  BMJ Case Rep       Date:  2017-02-14

6.  Blastomycosis-Induced Acute Respiratory Distress Syndrome.

Authors:  Maleeha Ajmal; Fahad Aftab Khan Lodhi; Gul Nawaz; Ahmad Basharat; Afifa Aslam
Journal:  Cureus       Date:  2022-02-14

Review 7.  Neurally Adjusted Ventilatory Assist in Acute Respiratory Failure-A Narrative Review.

Authors:  Michele Umbrello; Edoardo Antonucci; Stefano Muttini
Journal:  J Clin Med       Date:  2022-03-28       Impact factor: 4.241

Review 8.  Respiratory management in the patient with spinal cord injury.

Authors:  Rita Galeiras Vázquez; Pedro Rascado Sedes; Mónica Mourelo Fariña; Antonio Montoto Marqués; M Elena Ferreiro Velasco
Journal:  Biomed Res Int       Date:  2013-09-09       Impact factor: 3.411

9.  Evaluating peak inspiratory pressures and tidal volume in premature neonates on NAVA ventilation.

Authors:  Alison P Protain; Kimberly S Firestone; Neil L McNinch; Howard M Stein
Journal:  Eur J Pediatr       Date:  2020-07-06       Impact factor: 3.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.